Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Lenalidomide in Combination for Follicular and Marginal Zone Lymphoma

May 28, 2019, 15:34 PM
URL:
On May 28, 2019, the U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL).

Read FDA announcement.

Posted 5/28/2019

Leave a comment